Top Page
Wuxi Biologics (Cayman)
(OTC:2269)
Wuxi Biologics (Cayman) (2269) vs. iShares MSCI Hong Kong ETF (EWH)
Wuxi Biologics (Cayman) Business Overview & Revenue Model
Wuxi Biologics (Cayman) Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 18.68B | 17.03B | 15.27B | 10.29B | 5.61B |
| Gross Profit | 7.65B | 6.83B | 6.72B | 4.83B | 2.53B |
| EBITDA | 6.43B | 5.50B | 6.22B | 4.51B | 2.31B |
| Net Income | 3.36B | 3.40B | 4.42B | 3.39B | 1.69B |
Balance Sheet | |||||
| Total Assets | 56.98B | 56.58B | 49.56B | 44.03B | 28.96B |
| Cash, Cash Equivalents and Short-Term Investments | 10.71B | 11.24B | 8.71B | 11.13B | 8.48B |
| Total Debt | 4.94B | 4.56B | 4.42B | 4.30B | 3.33B |
| Total Liabilities | 11.50B | 12.56B | 13.35B | 11.33B | 8.06B |
| Stockholders Equity | 41.82B | 40.33B | 35.05B | 32.28B | 20.56B |
Cash Flow | |||||
| Free Cash Flow | 1.29B | 437.20M | -326.72M | -3.09B | -4.14B |
| Operating Cash Flow | 5.22B | 4.67B | 5.54B | 3.43B | 1.88B |
| Investing Cash Flow | -3.94B | -3.23B | -5.91B | -9.60B | -7.22B |
| Financing Cash Flow | -2.75B | 1.96B | -2.59B | 8.21B | 6.57B |
Wuxi Biologics (Cayman) Technical Analysis
Wuxi Biologics (Cayman) Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $102.33B | 28.37 | 8.17% | ― | 7.52% | -1.92% | |
65 Neutral | ¥345.58B | 10.59 | -2.88% | 2.67% | 11.80% | -6.84% | |
| $12.07B | 49.57 | 6.14% | 1.52% | ― | ― | ||
| $16.27B | ― | -0.72% | ― | ― | ― | ||
| $6.94B | 24.21 | 14.19% | 0.15% | ― | ― | ||
55 Neutral | HK$83.03B | ― | -8.98% | ― | -54.66% | -123.11% | |
51 Neutral | HK$33.78B | ― | -19.78% | ― | 25.96% | 39.58% |
Wuxi Biologics (Cayman) Corporate Events
WuXi Biologics (Cayman) Inc. announced that its substantial shareholder, WuXi Biologics Holdings Limited, has entered into a block trade agreement with Morgan Stanley & Co. International PLC to place 82,940,000 existing shares, representing approximately 2.04% of the company’s total issued share capital. This transaction will reduce the shareholding of Biologics Holdings from 14.36% to 12.32%, although it will remain a substantial shareholder. The announcement advises shareholders and potential investors to exercise caution as the placing may or may not proceed.
The most recent analyst rating on (HK:2269) stock is a Hold with a HK$23.40 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
WuXi Biologics (Cayman) Inc. announced the results of its Annual General Meeting held on June 6, 2025, where all proposed resolutions were approved by shareholders. Significant changes in the board include the retirement of Dr. Weichang Zhou and the appointment of Dr. Sherry Xuejun Gu as an executive director and member of the Strategy Committee, along with Dr. Jue Chen joining the Nomination Committee. These changes are expected to influence the company’s strategic direction and governance structure.
The most recent analyst rating on (HK:2269) stock is a Hold with a HK$23.40 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
WuXi Biologics (Cayman) Inc. has announced the composition of its board of directors and their roles within the company. The board includes executive, non-executive, and independent non-executive directors, with specific members assigned to various committees such as Audit, Remuneration, Nomination, Strategy, and Environmental, Social and Governance. This announcement reflects the company’s commitment to strong governance and strategic oversight, potentially impacting its operational efficiency and stakeholder confidence.
The most recent analyst rating on (HK:2269) stock is a Buy with a HK$30.94 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
Wuxi Biologics has announced the grant of 64,117 Restricted Shares under its Restricted Share Award Scheme to an independent third-party employee. This initiative is designed to motivate the grantee by offering a personal stake in the company, aligning with Wuxi Biologics’ customary practice of equity-based remuneration. The shares will vest over a five-year period, with a clawback mechanism in place for specific circumstances, ensuring the company’s interests are protected.
The most recent analyst rating on (HK:2269) stock is a Buy with a HK$30.94 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
Wuxi Biologics (Cayman) Inc. announced its Annual General Meeting to be held on June 6, 2025, in Shanghai, China. Key agenda items include the reception of audited financial statements for 2024, re-election and appointment of directors, authorization of directors’ remuneration, and re-appointment of auditors. Additionally, a resolution will be considered to grant directors the mandate to issue and allot shares, not exceeding 10% of the total issued shares, under specified conditions. This meeting is significant for stakeholders as it addresses corporate governance and strategic decisions impacting the company’s future operations.
The most recent analyst rating on (HK:2269) stock is a Buy with a HK$30.94 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
WuXi Biologics (Cayman) Inc. has announced a change in its principal place of business in Hong Kong, effective April 1, 2025. Additionally, the company has completed an asset transaction related to its Vaccines Ireland Facility, with a total consideration of approximately US$499.63 million. This transaction is expected to enhance WuXi Biologics’ capabilities in vaccine production, potentially strengthening its position in the global biologics market.